Daily Stock Analysis, APVO, Aptevo Therapeutics Inc, priceseries

Aptevo Therapeutics Inc. Daily Stock Analysis
Stock Information
Open
3.24
Close
3.11
High
3.24
Low
3.06
Previous Close
3.28
Daily Price Gain
-0.17
YTD High
10.22
YTD High Date
Jan 8, 2020
YTD Low
2.94
YTD Low Date
Mar 13, 2020
YTD Price Change
-5.89
YTD Gain
-65.44%
52 Week High
14.56
52 Week High Date
Jun 20, 2019
52 Week Low
2.94
52 Week Low Date
Mar 13, 2020
52 Week Price Change
-8.79
52 Week Gain
-73.87%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Dec 22. 2016
29.82
Jan 10. 2017
33.92
11 Trading Days
13.73%
Link
LONG
Sep 13. 2017
25.34
Oct 12. 2017
34.64
21 Trading Days
36.68%
Link
LONG
Oct 26. 2017
37.38
Oct 30. 2017
40.39
2 Trading Days
8.05%
Link
LONG
Dec 5. 2017
48.72
Dec 11. 2017
51.34
4 Trading Days
5.39%
Link
LONG
Apr 11. 2018
53.06
Apr 13. 2018
55.86
2 Trading Days
5.28%
Link
LONG
May 9. 2018
61.04
May 21. 2018
71.45
8 Trading Days
17.05%
Link
LONG
Aug 10. 2018
67.62
Aug 28. 2018
74.01
12 Trading Days
9.45%
Link
LONG
Jan 3. 2019
20.44
Jan 17. 2019
22.05
10 Trading Days
7.86%
Link
LONG
Jan 31. 2019
22.40
Feb 12. 2019
24.05
8 Trading Days
7.38%
Link
Company Information
Stock Symbol
APVO
Exchange
NasdaqGS
Company URL
http://-
Company Phone
206-838-0500
CEO
Marvin L. White
Headquarters
Washington
Business Address
2401 4TH AVE., SUITE 1050, SEATTLE, WA 98121
Sector
-
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001671584
About

Aptevo Therapeutics, Inc. focuses on novel oncology and hematology therapeutics to meaningfully improve patient's lives. It also products in the areas of hematology and infectious diseases, as well as various investigational stage product candidates in immune-oncology. Aptevo Therapeutics was founded on February 22, 2016 and is headquartered in Seattle, WA.

Description

Aptevo Therapeutics Inc., a biotechnology company, provides oncology and hematology therapeutics. Its marketed products include WinRho SDF for the treatment of autoimmune platelet disorders, as well as for the treatment of hemolytic disease of the newborn; and HepaGam B used for the prevention of hepatitis-B recurrence following liver transplantation in HBsAg-positive liver transplant patients, and for the treatment following exposure to hepatitis-B. The company's marketed products also comprise VARIZIG for use in treating following exposure to varicella zoster virus, which causes chickenpox in high-risk individuals; and IXINITY, which is indicated in adults and children 12 years of age and older with hemophilia B for control and prevention of bleeding episodes, and management of bleeding during operations. Its investigational stage product candidates include MOR209/ES414, ES210, ES425, and otlertuzumab used to expand on the utility and effectiveness of therapeutic antibodies; and 5E3 mAb, a monoclonal antibody therapeutic that is in pre-clinical development for Alzheimer's disease. The company was incorporated in 2016 and is based in Seattle, Washington. As of August 01, 2016, Aptevo Therapeutics Inc. operates independently of Emergent BioSolutions, Inc.